Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Doctoral Research Award: Canada Graduate Scholarships

McGill University

$105,000.00

Targeting the PDCD4-eIF4A axis to enhance anti-mitotic therapy

EF 2022-23

Résumé
Poor response to chemotherapy is a great concern for people treated for cancer and their loved ones. Taxol is an example of a chemotherapy drug commonly used to treat a wide range of cancers. Taxol kills cells by preventing them from multiplying. Cells, however, can become resistant to Taxol, allowing them to survive. Cells that overcome the toxicity of Taxol acquire abnormal changes to their DNA, which could further drive the progression of cancer. Thus, studying and targeting molecular pathways that contribute to Taxol resistance is greatly needed to improve treatment response. Our previous studies found that a gene called PDCD4 (programmed cell death 4) may be important in causing cells to die during Taxol treatment and preventing resistance. PDCD4 codes for a protein that limits cells from excessive growth and promotes cell death. Our initial data show that patients with different cancer subtypes express varying levels of PDCD4, which could explain why patients do not respond to Taxol therapy in the same way. In this research project, we will use different cancer cell models to study if PDCD4 indeed has an important role in facilitating cell death in response to Taxol. We predict that cancers with higher levels of PDCD4 will respond better to Taxol, while those with lower levels of PDCD4 will be more resistant. For those with lower PDCD4 levels, we will test if a drug that can mimic the effects of PDCD4 can be used in combination with Taxol to enhance drug response. Uncovering the cellular mechanisms of Taxol resistance will allow us to better predict which patients will likely respond well to Taxol, and which will not. Our findings will allow for the development of more personalized drug treatments for patients with cancer, thus improving their outcome.
Programme
Doctoral Research Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
475844
Name
Chen Owen J
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Targeting the PDCD4-eIF4A axis to enhance anti-mitotic therapy
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Research Award: Canada Graduate Scholarships
Keyworddelim
Anti-Mitotics; Cell Cycle; Eif4a; Mitosis; Mitotic Slippage; Programmed Cell Death 4; Taxol
Abstract
Poor response to chemotherapy is a great concern for people treated for cancer and their loved ones. Taxol is an example of a chemotherapy drug commonly used to treat a wide range of cancers. Taxol kills cells by preventing them from multiplying. Cells, however, can become resistant to Taxol, allowing them to survive. Cells that overcome the toxicity of Taxol acquire abnormal changes to their DNA, which could further drive the progression of cancer. Thus, studying and targeting molecular pathways that contribute to Taxol resistance is greatly needed to improve treatment response. Our previous studies found that a gene called PDCD4 (programmed cell death 4) may be important in causing cells to die during Taxol treatment and preventing resistance. PDCD4 codes for a protein that limits cells from excessive growth and promotes cell death. Our initial data show that patients with different cancer subtypes express varying levels of PDCD4, which could explain why patients do not respond to Taxol therapy in the same way. In this research project, we will use different cancer cell models to study if PDCD4 indeed has an important role in facilitating cell death in response to Taxol. We predict that cancers with higher levels of PDCD4 will respond better to Taxol, while those with lower levels of PDCD4 will be more resistant. For those with lower PDCD4 levels, we will test if a drug that can mimic the effects of PDCD4 can be used in combination with Taxol to enhance drug response. Uncovering the cellular mechanisms of Taxol resistance will allow us to better predict which patients will likely respond well to Taxol, and which will not. Our findings will allow for the development of more personalized drug treatments for patients with cancer, thus improving their outcome.
Competitiondate
202211
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Chen, Owen J
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~